JNJ
Johnson and Johnson $JNJ Not Moving. Kickback Schemes or Legitimate Marketing?: http://bit.ly/bpapAn
JNJ
Johnson and Johnson $JNJ Not Moving. Kickback Schemes or Legitimate Marketing?: http://bit.ly/dmAJOB
JNJ
Johnson and Johnson $JNJ Not Moving. With better handling Toyota can get its brand back on track: http://bit.ly/aI3ykw
JNJ
Johnson and Johnson $JNJ Not Moving. Kickback Schemes or Legitimate Marketing?: http://bit.ly/9eHyeE
JNJ
Congratulations to $JNJ CFO Dominic Caruso, voted as a 1st Place CFO by sell-side analystst - http://bit.ly/aUuhYU (via @irwebreport)
JNJ
Andrew Jones of E&Y points to $JNJ's Stelara & Allos' ($ALTH) Folotyn as 2009's novel drug approvals - Nature Reviews http://bit.ly/
JNJ
Thank heavens I didn't buy a Matrix in '08! Wow. It's no longer fair to compare $TM to $JNJ and Tylenol. This is a full-blown PR nightmare.
JNJ
Johnson and Johnson $JNJ Not Moving. ZACKS ANALYST BLOG HIGHLIGHTS: MASTERCARD INCORPORATED, BROA: http://bit.ly/cWdoq7
JNJ
Johnson and Johnson $JNJ Not Moving. Guvera Limited Launches Beta In Australia With Huge Success,: http://bit.ly/cEPf4n
JNJ
the Artificial Pancreas Project, $8 million partnership with Animas to develop a first-generation system http://bit.ly/94OirB $JNJ
JNJ
RT @jessefelder Toyota: How to Kill One of the Most Powerful Brands in the World http://bit.ly/deCgJ7 $TM $JNJ
JNJ
Toyota: How to Kill One of the Most Powerful Brands in the World http://bit.ly/deCgJ7 $TM $JNJ
JNJ
Stocks Going Ex Dividend 3rd Week of Feb http://bit.ly/9q9ASo $JNJ $BOH $HSY
JNJ
Johnson and Johnson $JNJ Not Moving. Market Focus with Tom Hudson: http://bit.ly/cr7w62
JNJ
Johnson and Johnson $JNJ Not Moving. Market Focus with Tom Hudson: http://bit.ly/9mz5eF
JNJ
.@mommadona My core Trading Portfolio consists of $MMM, $WAG, $TJX, $T, $CHD, $MCD, $JNJ, and $SYY and 14% cash. $$
JNJ
Johnson and Johnson $JNJ Dropped Over Half A Percent. Downturn presents new lease of life for Indian drug firms: http://bit.ly/dgLV52
JNJ
Johnson and Johnson $JNJ Dropped Over Half A Percent. Downturn presents new lease of life for Indian drug firms: http://bit.ly/9Jb4Ni
JNJ
Johnson and Johnson $JNJ Went Up Over 1%. Unilever, Diageo and J&J among winners in awards for new: http://bit.ly/bzJ6BB
JNJ
Unusual Movement: $DIS( Vol 38%,S1,R1,3dLow,2dHihg) $JNJ( Vol 59%,S1,R2,3dLow,2dHigh) $MMM( Vol 61%,S1,R1,3dLow,2dHigh)
JNJ
CAPS Members Bullish on $WU Also Bullish on $GE and $JNJ http://www.urltwit.com//nx
JNJ
CAPS Members Bullish on $WU Also Bullish on $GE and $JNJ http://www.urltwit.com//nx
JNJ
http://bit.ly/bH0rP6 $BSX $JNJ Boston Scientific to Pay $1.7 Billion to Settle Patent Suits
JNJ
$BSX v/s $JNJ - Huge Pay day for Johnson & Johnson! Boston Scientific to pay JNJ $1.73B in settlement - http://bit.ly/cujvL9 $$
JNJ
Johnson and Johnson $JNJ A Little Up. Watson inks generics deal with Indian pharma; J&J to get: http://bit.ly/aJolMV
JNJ
Johnson and Johnson $JNJ Now Trading. Boston Scientific Corporation (BSX) to Pay Johnson & Joh: http://bit.ly/brjYio
JNJ
Boston Sci Pays J&J $1.7B to End Stent Patent Dispute - Stocks To Watch Today - Barrons.com $BSX $JNJ http://bit.ly/cru4ee
JNJ
Reuters: Boston Scientific to pay J&J $1.73B to settle stent patent fights. $BSX $JNJ
JNJ
Albert-Culver Off on Q1 Revenue Miss - Stocks To Watch Today - Barrons.com $ACV $BARE $REV $JNJ $CL $PG http://bit.ly/bol8nE
Johnson & Johnson - JNJ Insiders
No Insiders
We have no insiders for Johnson & Johnson right now.
Know someone who is an insider on Johnson & Johnson?
Let us know.
Johnson & Johnson - JNJ information
Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide. Its Consumer segment provides products used in baby care, skin care, oral care, wound care, and women?s health care fields, as well as nutritional and over-the-counter pharmaceutical products under JOHNSON?S, AVEENO, CLEAN & CLEAR, NEUTROGENA, RoC, LUBRIDERM, LISTERINE, REACH, CAREFREE, STAYFREE, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID AC names. The company?s Pharmaceutical segment offers products in various therapeutic areas, such as anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology, and virology. Its products include REMICADE, a biologic to treat Crohn?s disease, ankylosing spondylitis, psoriasis, psoriatic arthritis, ulcerative colitis, and used to treat rheumatoid arthritis; TOPAMAX, for adjunctive and monotherapy use in epilepsy, as well as for treating migraines; PROCRIT that stimulates red blood cell production; RISPERDAL oral, a medication to treat the symptoms of schizophrenia, bipolar mania, and irritability associated with autistic behavior in indicated patients; RISPERDAL CONSTA, an injectable, and INVEGATM Extended-Release tablets to treat schizophrenia; LEVAQUIN and FLOXIN, anti-infective products; CONCERTA, a product for treating attention deficit hyperactivity disorder; ACIPHEX/PARIET, a proton pump inhibitor; and DURAGESIC/Fentanyl Transdermal, a treatment for chronic pain. Johnson & Johnson?s Medical Devices and Diagnostics segment offers circulatory disease management, orthopaedic joint reconstruction and spinal care and sports medicine, surgical care and women?s health, minimally invasive surgical, blood glucose monitoring and insulin delivery, and diagnostic products, as well as disposable contact lenses. The company was founded in 1886 and is based in New Brunswick, New Jersey....
www.jnj.com
115,500 Employees
Founded in 1886
JOHNSON & JOHNSON (JNJ:New York)
LAST $58.61 USD
CHANGE TODAY +0.32 0.55%
VOLUME 8.1M
As of 8:04 PM 09/2/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of JOHNSON & JOHNSON (JNJ)
|
OPEN
$58.52
|
PREVIOUS CLOSE
$58.29
|
|
|
DAY HIGH
$58.79
|
DAY LOW
$58.30
|
|
|
52 WEEK HIGH
04/20/10 - $66.20
|
52 WEEK LOW
07/22/10 - $56.86
|
|
|
MARKET CAP
161.4B
|
AVERAGE VOLUME 10 D
11.9M
|
|
|
EPS TTM
$4.72
|
SHARES OUTSTANDING
2.8B
|
|
|
EX-DATE
08/27/10
|
P/E TTM
12.4x
|
|
|
DIVIDEND
$2.16
|
DIVIDEND YIELD
3.51%
|
|
| K = Thousands M = Millions B = Billions | ||
related news
Final Glance: Pharmaceuticals companies
AP Digital - 09/02/2010 6:05 PM ET
Final Glance: Medical Devices companies
AP Digital - 09/02/2010 6:04 PM ET
Midday Glance: Pharmaceuticals companies
AP Digital - 09/02/2010 1:17 PM ET
Midday Glance: Medical Devices companies
AP Digital - 09/02/2010 1:17 PM ET
Early Glance: Pharmaceuticals companies
AP Digital - 09/02/2010 10:32 AM ET
Key developments for JOHNSON & JOHNSON (JNJ)
Johnson & Johnson Presents at 5th eDiscovery for Pharma, Biotech & Medical Device Industries Conference, Sep-14-2010 11:45 AM
08/26/2010
Johnson & Johnson Presents at 5th eDiscovery for Pharma, Biotech & Medical Device Industries Conference, Sep-14-2010 11:45 AM. Venue: The Hub-CHF Center, 315 Chestnut Street, Philadelphia, PA 19106-2702, United States. Speakers: Deena Coffman, Senior Manager, Deloitte, Former Discovery Director.
Johnson & Johnson expected to report Fiscal Year 2010 results on January 25, 2011. This event was calculated by Capital IQ (Created on August 22, 2010).
08/22/2010
Johnson & Johnson expected to report Fiscal Year 2010 results on January 25, 2011. This event was calculated by Capital IQ (Created on August 22, 2010).
Johnson & Johnson Creates New Quality Control Position
08/18/2010
Johnson & Johnson is creating a new position to oversee companywide quality, manufacturing and compliance issues and appointing chief quality officers for each of its three major business units. The company named corporate Vice President Ajit Shetty to oversee the push for quality improvements in its pharmaceutical, consumer products and medical device and diagnostics groups.
JNJ Competitors
| Company | Last | Change |
| Archer-Daniels-Midland Co | $31.54 USD | +0.19 |
| Novartis AG | SFr.53.70 CHF | -0.35 |
| Pfizer Inc | $16.40 USD | +0.12 |
| Dow Chemical Co/The | $25.88 USD | +0.29 |
| Unilever NV | €21.35 EUR | -0.175 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | JNJ | Industry Range |
| Price/Earnings | 12.0x |
|
| Price/Sales | 2.6x |
|
| Price/Book | 3.0x |
|
| Price/Cash Flow | 11.9x |
|
| TEV/Sales | 2.1x |
|
|
JNJ |
||
|
JNJ transactions
| Type Date |
Target |
|
Merger/Acquisition
August 3, 2010 |
Movetis NV |
Johnson & Johnson - JNJ news
Chuck Jaffe: Make this stockpicker's market work for you
2010-09-02 05:33:53
Keywords: Investing|Stocks, JNJ, Johnson & Johnson
Quote: Read article
J&J: More Recalls, More Market Share Loss?
2010-09-01 07:17:02
Keywords: Financial, News, Stock, Market, Headlines, Investments, Quotes, Trading, TheStreet.com, Andrea Tse ,Consumer Goods
Quote: (Recall story updated with more analyst commentary and stock price)NEW YORK (TheStreet) -- What will be the financial impact of recalls by Johnson & Johnson's(JNJ)DePuy Orthopaedics unit of two hip replacement devices and the company's recent contact lens recalls -- only days after receiving a warning letter from the U.S. Food and Drug Administration for violating FDA rules by marketing two orthopedic products without proper approval or clearance?According to many observers, it will likely be a ...Read article
Bayer says data encouraging, wary on read-across
2010-08-31 09:17:43
Keywords: Pharmaceuticals - Diversified,Chemicals,Germany,Western Europe,Europe,Sweden,Biotechnology / Pharmaceuticals,United States,Healthcare,Pharmaceuticals,Pharmaceuticals / Medical Research,Central/Eastern Europe,Eurozone countries,Company News item,Economic n
Quote: Read article
[$$] J&J Chief Tends Corporate Wounds
2010-08-30 08:49:10
Quote: ROCKOFF At a recent town-hall meeting, Johnson & Johnson Chief Executive William Weldon sketched out for employees his plans for fixing the manufacturing problems that have prompted a string of recalls and triggered a criminal investigation. Now, he faces the more difficult task of executing those plans and convincing the public that J&J has put its problems behind it. His success—or failure—may be among the most important legacies he leaves the company near the end of a four-decade...Read article
How To Protect Your Bond Holdings From Rising Interest Rates
2010-08-27 07:20:34
Keywords: bonds, risk, interest rates, treasuries, duration
Quote: Read article
[$$] J&J Latest Recall: Hip-Repair Implants
2010-08-27 07:20:33
Quote: ROCKOFFAND JON KAMPJohnson & Johnson pulled two hip-repair implants off the market Thursday, the latest in a string of products recalled because of quality problems. J&J's DePuy Orthopaedics Inc. unit said Thursday it is recalling the hip implants because too many patients needed surgeries to replace the devices. The unit had sold about 93,000 of the devices before phasing out production last year. The company said it's withdrawing the "very few" left on the market because new data indicated su...Read article
DePuy Orthopaedics Voluntarily Recalls ASR Hip System
2010-08-26 09:53:06
Keywords: DePuy Orthopaedics Voluntarily Recalls ASR Hip System, jnj
Quote: and/or Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment.Ã...Read article
UPDATE - J&J ortho unit recalls hip replacement systems
2010-08-26 09:53:05
Keywords: Biotechnology / Pharmaceuticals,United States,United Kingdom,Western Europe,Europe,Pharmaceuticals - Diversified,Healthcare,Pharmaceuticals,Pharmaceuticals / Medical Research,Company News item,Economic news, EC, business/financial pages,
Quote: Read article
Sector Snap: Medtronic 1Q drags down device sector
2010-08-25 08:16:01
Keywords: Sector Snap: Medtronic 1Q drags down device sector, bsx,jnj,mdt,stj,syk, stocks
Quote: Johnson & Johnson shares were down 83 cents at $58.04.Medtronic, Boston Scientific Corp. and other device makers have struggled in recent years to make up for slowing sales of their top-selling products, implantable defibrillators and stents, which have been hurt by safety concerns and increased pricing competition.Defibrillators are implanted in the chest and use electrical jolts to correct deadly irregular heart rhythms. The devices are Medtronic's top-selling franchise, though company managem...Read article
FDA warns J&J unit for illegally marketing hip device
2010-08-25 08:16:00
Keywords: Johnson & Johnson, Food and Drug Administration, warning letter, FDA, Depuy Orthopaedics
Quote: Read article
[$$] J&J Contact Lenses Recalled
2010-08-24 07:33:34
Quote: ROCKOFFAND JON KAMPJohnson & Johnson, which is trying to fix problems making Tylenol and other popular over-the-counter medicines, said Monday it was recalling about 100,000 boxes of contact lenses sold in Asia and Europe because of a manufacturing problem. J&J's Vision Care Inc. unit recalled the "1-Day Acuvue TruEye" lenses after customers in Japan complained about experiencing pain, stinging or redness after inserting the lenses, the company said. Two lens customers were treated with medica...Read article
What "The Oracle of the North" Sees Ahead
2010-08-20 03:56:01
Keywords: What
Quote: And while the company has been cutting its exposure in equities, it has maintained its large position in two companies: Johnson & JohnsonJNJNews), and KraftKFTNews). Each company is a dominant contender at a very reasonable price. They also do a large percentage of their business abroad.The Foolish bottom lineIf we are trusting Watsa to be right again (and that is usually the smart-money bet), U.S. investors are in for a volatile ride. But individual opportunities exist, especially in investment...Read article
Johnson & Johnson adding more quality control after recalls
2010-08-19 06:36:38
Keywords: tylenol, tylenol recall, johnson & johnson, johnson & johnson recalls, tylenol quality, johnson & johnson quality control
Quote: Read article